Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications

Clinical Chemistry

Volumn 45, Issue 8 I, 1999, Pages 1148-1156

  Bièche, Ivan ^a,b   Onody, Peter ^b   Laurendeau, Ingrid ^a   Olivi, Martine ^a   Vidaud, Dominique ^a   Lidereau, Rosette ^b   Vidaud, Michel ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; ONCOGENE NEU; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE PREPARATION;

EID: 0141542480     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.8.1148     Document Type: Article

References (37)

1. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
2. Slamon DJ, Clark GM, Wong SG, Levin WS, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 177-82.
3. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049-56.
4. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330: 1260-6.
5. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60.
6. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79:1220-6.
7. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997;3: 593-600.
8. Nass SJ, Hahm HA, Davidson NE. Breast cancer biology blossoms in the clinic. Nat Med 1998;4:761-2.
9. Clark GM. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J Natl Cancer Inst 1998;90:1320-1.
10. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
11. Pauletti G, Godolphin W, Press MF, Salmon DJ. Detection and quantification of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
12. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
13. Gibson UEM, Heid CA, Wiiliams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.
14. Celi FS, Cohen MM, Antonarakis SE, Wertheimer E, Roth J, Shuldiner AR. Determination of gene dosage by a quantitative adaptation of the polymerase chain reaction (gd-PCR): rapid detection of deletions and duplications of gene sequences. Genomics 1994;21:304-10.
15. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′ to 3′ exonucloase activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 1991;88:7276-80.
16. Bièche I, Olivi M, Champeme M-H, Vidaud D, Lidereau R, Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection; application to the detection of gene amplification in breast cancer. Int J Cancer 1998;78:661-6.
17. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
18. EORTC. Breast Cooperative Group revision. Revision of the standards for the assessment of hormone receptors in human breast cancer. Report of the second EORTC workshop. Eur J Cancer 1980;16:1513-5.
19. Dirnhofer S, Berger C, Untergasser G, Geley S, Berger R. Human β-actin retropseudogenes interfere with RT-PCR. Trends Genet 1995;11:380-1.
20. Sellner LN, Turbett GR. The presence of a pseudogene may affect the use of HPRT as an endogenous mRNA control in RT-PCR. Mol Cell Probes 1996;10:481-3.
21. Mullen CA. Review: analogies between trophoblastic and malignant cells. Am J Reprod Immunol 1998;39:41-9.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
25. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
26. Hoyle R. Genentech is poised for an anti-cancer breakthrough. Nat Biotechnol 1998;16:887.
27. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
28. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, et al. Overexpression of both p185c-erbB2 and p170 mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998;16-2087-94.
29. Kononen J, Bubendorf L, Kallioniemi A, Bārlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
30. Colomer R, Lupu R, Bacus SS, Gelman EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 1994;70:819-25.
31. Porumb H, Gousset H, Letellier R, Salle V, Briane D, Vassy J, et al. Temporary ex vivo inhibition of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide. Cancer Res 1996;56: 512-22,
32. Courjal F, Cuny M, Simony-Lafontaine J, Louasson G, Speiser P, Zeillinger R, et al. Mapping of DNA amplification at 15 chromosomal localization in 1875 breast tumors; definition of phenotypic groups. Cancer Res 1997;57:4360-7.
33. Revillion F, Hornez L, Peyrat J-P. Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR. Clin Chem 1997;43:2114-20.
34. Hynes NE, Geber HA, Saurer S, Groner B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem 1989;39:145-51.
35. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34: 791-808.
36. Koscielny S. Prognostic importance of low c-erbB2 expression in breast tumors J Natl Cancer Inst 1998;90:712.
37. Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993;13:2247-57.